CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 89 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2009-04-30 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.33 | $8K | 8,850,093 |
| 2009-04-29 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.37 | $9K | 8,825,093 |
| 2009-04-28 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.36 | $9K | 8,800,093 |
| 2009-04-24 | Ramachandran Kartik V. Chief Strat Off, EVP Bus Dev | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2009-04-24 | Glassman Nicholas A EVP of Product and Technology | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2009-04-10 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.24 | $6K | 8,775,093 |
| 2009-04-06 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.27 | $7K | 8,750,093 |
| 2009-03-20 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +40,200 | $0.23 | $9K | 8,700,093 |
| 2009-03-20 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +25,000 | $0.22 | $5K | 8,725,093 |
| 2009-03-19 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +10,000 | $0.20 | $2K | 8,659,893 |
| 2009-03-16 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +11,500 | $0.23 | $3K | 8,629,893 |
| 2009-03-16 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +20,000 | $0.20 | $4K | 8,649,893 |
| 2009-03-11 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +100,160 | $0.22 | $22K | 8,618,393 |
| 2009-02-13 | Lewis Mary Beth Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2009-02-02 | Bateman Terry Allan CEO | Grant or award · Stock Option (Right to Buy) | +1,750,000 | 1,750,000 | ||
| 2009-01-30 | Arzt Michael A Executive VP of Marketing | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2009-01-22 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +27,700 | $0.22 | $6K | 8,518,233 |
| 2009-01-07 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +75,341 | $0.15 | $11K | 8,490,533 |
| 2009-01-02 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +35,000 | $0.14 | $5K | 8,415,192 |
| 2008-12-31 | Trinad Capital Master Fund Ltd. 10% owner | Purchase | +345,800 | $0.14 | $48K | 8,380,192 |
Page 30 of 33 · 657 trades